Mivebresib|ABBV-075（ABBV075）|BET/MYC inhibitor
Mivebresib in stock, 800 USD/100mg. Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins
Product Name: Mivebresib(ABBV-075） |cas: 1445993-26-9 |cat number: DC9836 |Molecule Formular: C22H19F2N3O4S |MW: 459.47 |purity>98%
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins. Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.
For research only, not for human use.
没有评论:
发表评论